Apic Bio is committed to finding cures for patients with genetic diseases. The company is a spin-off from the University of Massachusetts Medical School (UMMS) and is based upon nearly 30 years of gene therapy research by Apic's scientific founders. Apic is developing best-in-class treatment options for rare, devastating neurological and liver diseases. Its current pipeline focuses on new and effective treatments for Alpha-1 Antitrypsin Deficiency (Alpha-1, or AATD) and genetic Amyotrophic Lateral Sclerosis (ALS.)
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/08/19 | $40,000,000 | Series A |
A1ATD Investors Alpha-1 Project ALS Investment Fund Morningside Venture  | undisclosed |
